Exp Clin Endocrinol Diabetes 2016; 124(03): 140-147
DOI: 10.1055/s-0035-1569374
Article
© Georg Thieme Verlag KG Stuttgart · New York

Factors Associated with Higher Pro-Inflammatory Tumor Necrosis Factor-α Levels in Young Women with Type 1 Diabetes

K. K. Danielson
1   Division of Transplant Surgery, College of Medicine, University of Illinois at Chicago
2   Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago
,
R. S. Monson
1   Division of Transplant Surgery, College of Medicine, University of Illinois at Chicago
,
T. J. LeCaire
3   Department of Population Health Sciences, University of Wisconsin-Madison
› Author Affiliations
Further Information

Publication History

received 13 August 2015
first decision 09 December 2015

accepted 16 December 2015

Publication Date:
23 March 2016 (online)

Abstract

Aims: While cytokines play a role in the etiology of type 1 diabetes, cytokines later in the disease are less understood. We therefore investigated associations of pro-inflammatory tumor necrosis factor-α levels measured at prolonged disease duration with C-peptide at diagnosis, long-term glycemic control, diabetes duration, clinical factors, and health behaviors.

Methods: Data and blood were collected during an ancillary study to the longitudinal Wisconsin Diabetes Registry, a population-based cohort followed since diagnosis of type 1 diabetes. The ancillary study was conducted at 13–18 years diabetes duration, and enrolled premenopausal women age 18–45 years (n=87).

Results: Higher tumor necrosis factor-α levels at 13–18 years diabetes duration were independently associated with longer duration (p=0.0004) and worse current renal function (p=0.02). Additionally, diabetes duration modified both of the positive associations of tumor necrosis factor-α levels (both interactions p≤0.01) with mean glycemic control during the previous 10 years (significant only in women with longer durations) and current daily caffeine intake (significant only in women with shorter durations). In women with C-peptide measured at diagnosis (n=50), higher tumor necrosis factor-α levels at 13–18 years duration were associated with lower C-peptide (p=0.01), independent of glycemic control during the previous 10 years.

Conclusions: Lower residual C-peptide at diagnosis and poor long-term glycemic control independently predicted higher pro-inflammatory tumor necrosis factor-α levels years later. The novel relationship with C-peptide needs confirmation in a larger cohort. Given the association between tumor necrosis factor-α and diabetes complications, further longitudinal studies may help clarify the potentially complex associations between glycemic control, inflammatory cytokines, and complications.

 
  • References

  • 1 Nathan DM, Cleary PA, Backlund JY et al. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653
  • 2 Bell RA, Mayer-Davis EJ, Beyer JW et al. The SEARCH for Diabetes in Youth Study Group. Diabetes in non-hispanic white youth: Prevalence, incidence, and clinical characteristics. Diabetes Care 2009; 32 (Suppl. 02) S102-S111
  • 3 Pettitt DJ, Talton J, Dabelea D et al. Prevalence of diabetes in U.S. youth in 2009: The SEARCH for Diabetes in Youth Study. Diabetes Care 2014; 37: 402-408
  • 4 Rabinovitch A, Suarez-Pinzon WL. Roles of cytokines in the pathogenesis and therapy of type 1 diabetes. Cell Biochem Biophys 2007; 48: 159-163
  • 5 Padgett LE, Broniowska KA, Hansen PA et al. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci 2013; 1281: 16-35
  • 6 Ozer G, Teker Z, Cetiner S et al. Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings. J Pediatr Endocrinol Metab 2003; 16: 203-210
  • 7 Kaas A, Pfleger C, Kharagjitsingh AV et al. The Hvidoere Study Group on Childhood Diabetes. Association between age, IL-10, IFNgamma, stimulated C-peptide and disease progression in children with newly diagnosed type 1 diabetes. Diabet Med 2012; 29: 734-741
  • 8 Erbagci AB, Tarakcioglu M, Coskun Y et al. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem 2001; 34: 645-650
  • 9 Basu S, Larsson A, Vessby J et al. Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care 2005; 28: 1371-1375
  • 10 Espersen GT, Mathiesen O, Grunnet N et al. Cytokine plasma levels and lymphocyte subsets in patients with newly diagnosed insulin-dependent (type 1) diabetes mellitus before and following initial insulin treatment. APMIS 1993; 101: 703-706
  • 11 Schram MT, Chaturvedi N, Schalkwijk CG et al. Eurodiab Prospective Complications Study Group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes – the EURODIAB Prospective Complications Study. Diabetologia 2005; 48: 370-378
  • 12 Zorena K, Kula M, Malinowska E et al. Threshold serum concentrations of tumour necrosis factor alpha (TNF alpha) as a potential marker of the presence of microangiopathy in children and adolescents with type 1 diabetes mellitus (T1DM). Hum Immunol 2013; 74: 75-81
  • 13 Machnica L, Deja G, Polanska J et al. Blood pressure disturbances and endothelial dysfunction markers in children and adolescents with type 1 diabetes. Atherosclerosis 2014; 237: 129-134
  • 14 Pfleger C, Mortensen HB, Hansen L et al. Hvidore Study Group on Childhood Diabetes. Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 2008; 57: 929-937
  • 15 Esposito K, Nappo F, Marfella R et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072
  • 16 Lechleitner M, Koch T, Herold M et al. Tumor necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycemic control and cardiovascular risk factors. J Intern Med 2000; 248: 67-76
  • 17 Targher G, Zenari L, Bertolini L et al. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care 2001; 24: 956-957
  • 18 Reis JS, Amaral CA, Volpe CM et al. Oxidative stress and interleukin-6 secretion during the progression of type 1 diabetes. Arq Bras Endocrinol Metabol 2012; 56: 441-448
  • 19 Snell-Bergeon JK, West NA, Mayer-Davis EJ et al. Inflammatory markers are increased in youth with type 1 diabetes: The SEARCH Case-Control study. J Clin Endocrinol Metabol 2010; 95: 2868-2876
  • 20 Palta M, LeCaire T, Daniels K et al. Risk factors for hospitalization in a cohort with type 1 diabetes. Wisconsin Diabetes Registry. Am J Epidemiol 1997; 146: 627-636
  • 21 Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985; 727: 1-113
  • 22 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197
  • 23 Danielson KK, Elliott ME, LeCaire T et al. Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes. Osteoporos Int 2009; 20: 923-933
  • 24 Konecna L, Yan MS, Miller LE et al. Modulation of IL-6 production during the menstrual cycle in vivo and in vitro. Brain, Behav Immun 2000; 14: 49-61
  • 25 Svensson J, Eising S, Hougaard DM et al. Few differences in cytokines between patients newly diagnosed with type 1 diabetes and their healthy siblings. Hum Immunol 2012; 73: 1116-1126
  • 26 Willett WC, Sampson L, Stampfer MJ et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985; 122: 51-65
  • 27 Sallis JF, Haskell WL, Wood PD et al. Physical activity assessment methodology in the Five-City Project. Am J Epidemiol 1985; 121: 91-106
  • 28 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
  • 29 Stevens LA, Coresh J, Schmid CH et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406
  • 30 Palta M, Shen G, Allen C et al. Longitudinal patterns of glycemic control and diabetes care from diagnosis in a population-based cohort with type 1 diabetes. The Wisconsin Diabetes Registry. Am J Epidemiol 1996; 144: 954-961
  • 31 Allen C, Zaccaro DJ, Palta M et al. Glycemic control in early IDDM. The Wisconsin Diabetes Registry. Diabetes Care 1992; 15: 980-987
  • 32 Duck SC, Lee M, D’Alessio D. 24-42 month stability of internal blood standards for glycated hemoglobin analysis. Diabetes Res Clin Pract 1990; 9: 195-199
  • 33 Gjessing HJ, Matzen LE, Faber OK et al. Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 1989; 32: 305-311
  • 34 Preciado-Puga MC, Malacara JM, Fajardo-Araujo ME et al. Markers of the progression of complications in patients with type 2 diabetes: a one-year longitudinal study. Exp Clin Endocrinol Diabetes 2014; 122: 484-490
  • 35 Steffes MW, Sibley S, Jackson M et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-836
  • 36 Gonzalez-Clemente JM, Gimenez-Perez G, Richart C et al. The tumour necrosis factor (TNF)-alpha system is activated in accordance with pulse pressure in normotensive subjects with type 1 diabetes mellitus. Eur J Endocrinol 2005; 153: 687-691
  • 37 Zampelas A, Panagiotakos DB, Pitsavos C et al. Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study. Am J Clin Nutr 2004; 80: 862-867
  • 38 Horrigan LA, Kelly JP, Connor TJ. Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol 2004; 4: 1409-1417
  • 39 van Furth AM, Seijmonsbergen EM, Langermans JA et al. Effect of xanthine derivates and dexamethasone on Streptococcus pneumoniae-stimulated production of tumor necrosis factor alpha, interleukin-1 beta (IL-1 beta), and IL-10 by human leukocytes. Clin Diagn Lab Immunol 1995; 2: 689-692
  • 40 Deswal A, Petersen NJ, Feldman AM et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-2059
  • 41 Rordorf R, Savastano S, Sanzo A et al. Tumor necrosis factor-alpha predicts response to cardiac resynchronization therapy in patients with chronic heart failure. Circ J 2014; 78: 2232-2239